| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart Failure | 63 | 2019 | 6638 | 3.50 | Why? |
| Platelet Aggregation Inhibitors | 8 | 2019 | 1671 | 1.15 | Why? |
| Atrial Fibrillation | 18 | 2019 | 2320 | 1.11 | Why? |
| Sulfonylurea Compounds | 3 | 2019 | 79 | 1.05 | Why? |
| Stroke Volume | 19 | 2019 | 2153 | 1.02 | Why? |
| Registries | 40 | 2020 | 12327 | 1.01 | Why? |
| Defibrillators, Implantable | 7 | 2019 | 624 | 1.01 | Why? |
| Aspirin | 8 | 2019 | 1043 | 0.97 | Why? |
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2019 | 49 | 0.95 | Why? |
| Cardiovascular Diseases | 25 | 2020 | 11497 | 0.91 | Why? |
| Acute Coronary Syndrome | 8 | 2020 | 2107 | 0.90 | Why? |
| Rivaroxaban | 7 | 2019 | 467 | 0.89 | Why? |
| Fatty Acids, Omega-3 | 3 | 2019 | 306 | 0.77 | Why? |
| Adrenergic beta-Antagonists | 9 | 2018 | 465 | 0.74 | Why? |
| Oxazolidinones | 1 | 2018 | 49 | 0.72 | Why? |
| Cardiology | 12 | 2020 | 2873 | 0.72 | Why? |
| Hypoglycemic Agents | 12 | 2020 | 2165 | 0.69 | Why? |
| Therapies, Investigational | 1 | 2020 | 235 | 0.69 | Why? |
| Secondary Prevention | 5 | 2019 | 762 | 0.67 | Why? |
| Cardiac Resynchronization Therapy | 1 | 2018 | 191 | 0.60 | Why? |
| Atherosclerosis | 3 | 2019 | 768 | 0.60 | Why? |
| Anticholesteremic Agents | 1 | 2018 | 186 | 0.60 | Why? |
| Ischemic Attack, Transient | 1 | 2019 | 439 | 0.59 | Why? |
| Hypolipidemic Agents | 2 | 2017 | 208 | 0.58 | Why? |
| Pregnancy Complications, Cardiovascular | 4 | 2019 | 231 | 0.54 | Why? |
| Tetrazoles | 5 | 2019 | 262 | 0.52 | Why? |
| Diuretics | 5 | 2019 | 326 | 0.52 | Why? |
| Death, Sudden, Cardiac | 5 | 2018 | 522 | 0.51 | Why? |
| Societies, Medical | 12 | 2020 | 6907 | 0.50 | Why? |
| Valsartan | 6 | 2019 | 206 | 0.50 | Why? |
| Coronary Artery Disease | 5 | 2019 | 2570 | 0.49 | Why? |
| Cause of Death | 17 | 2019 | 4823 | 0.49 | Why? |
| Chronic Disease | 11 | 2020 | 5139 | 0.48 | Why? |
| Device Removal | 3 | 2019 | 221 | 0.47 | Why? |
| Drug Prescriptions | 6 | 2021 | 1062 | 0.46 | Why? |
| Health Care Costs | 2 | 2018 | 1007 | 0.46 | Why? |
| Europe | 34 | 2020 | 12702 | 0.46 | Why? |
| Diabetes Mellitus, Type 2 | 12 | 2019 | 6166 | 0.45 | Why? |
| Guideline Adherence | 5 | 2019 | 2309 | 0.43 | Why? |
| Mineralocorticoid Receptor Antagonists | 6 | 2018 | 203 | 0.43 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.43 | Why? |
| Cardiovascular Agents | 4 | 2019 | 663 | 0.42 | Why? |
| Pacemaker, Artificial | 4 | 2019 | 431 | 0.42 | Why? |
| Catheter Ablation | 4 | 2019 | 438 | 0.42 | Why? |
| Peripheral Arterial Disease | 4 | 2019 | 471 | 0.41 | Why? |
| Clinical Trials as Topic | 7 | 2020 | 7330 | 0.40 | Why? |
| Double-Blind Method | 18 | 2019 | 5988 | 0.40 | Why? |
| Lipids | 1 | 2017 | 1079 | 0.40 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2019 | 1510 | 0.40 | Why? |
| Community Health Services | 1 | 2018 | 1000 | 0.39 | Why? |
| Factor Xa Inhibitors | 3 | 2019 | 490 | 0.39 | Why? |
| Anticoagulants | 11 | 2020 | 9563 | 0.38 | Why? |
| Natriuretic Peptide, Brain | 6 | 2019 | 1215 | 0.38 | Why? |
| Practice Patterns, Physicians' | 6 | 2019 | 4927 | 0.38 | Why? |
| Anti-Arrhythmia Agents | 4 | 2019 | 325 | 0.37 | Why? |
| Gastrointestinal Hemorrhage | 3 | 2019 | 669 | 0.37 | Why? |
| Angiotensin Receptor Antagonists | 9 | 2019 | 3892 | 0.37 | Why? |
| Follow-Up Studies | 28 | 2019 | 17020 | 0.36 | Why? |
| Stroke | 9 | 2019 | 8839 | 0.36 | Why? |
| Research Design | 4 | 2020 | 5830 | 0.36 | Why? |
| Soluble Guanylyl Cyclase | 2 | 2017 | 11 | 0.35 | Why? |
| Heterocyclic Compounds, 2-Ring | 2 | 2017 | 29 | 0.35 | Why? |
| Venoms | 2 | 2017 | 24 | 0.35 | Why? |
| Income | 1 | 2017 | 1564 | 0.34 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 4 | 2018 | 520 | 0.34 | Why? |
| Pharmacists | 1 | 2018 | 1246 | 0.34 | Why? |
| Renin-Angiotensin System | 3 | 2018 | 3661 | 0.32 | Why? |
| Hospitalization | 22 | 2020 | 54280 | 0.32 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 206 | 0.32 | Why? |
| Randomized Controlled Trials as Topic | 12 | 2020 | 10649 | 0.31 | Why? |
| Aged | 80 | 2021 | 215776 | 0.31 | Why? |
| Glucagon-Like Peptide-1 Receptor | 2 | 2017 | 138 | 0.31 | Why? |
| Valine | 2 | 2007 | 359 | 0.31 | Why? |
| Peptide Fragments | 6 | 2019 | 2075 | 0.30 | Why? |
| Disease Management | 8 | 2020 | 6841 | 0.30 | Why? |
| Survival Rate | 17 | 2018 | 9206 | 0.30 | Why? |
| Cardiotonic Agents | 3 | 2017 | 418 | 0.30 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.29 | Why? |
| Humans | 127 | 2021 | 930598 | 0.29 | Why? |
| Drug Therapy, Combination | 13 | 2019 | 7268 | 0.27 | Why? |
| Proton Pump Inhibitors | 2 | 2019 | 377 | 0.27 | Why? |
| Aminobutyrates | 3 | 2019 | 142 | 0.26 | Why? |
| Time Factors | 27 | 2019 | 31397 | 0.26 | Why? |
| Female | 90 | 2021 | 380317 | 0.26 | Why? |
| Treatment Outcome | 32 | 2019 | 51732 | 0.26 | Why? |
| Male | 87 | 2021 | 367725 | 0.25 | Why? |
| Prospective Studies | 30 | 2019 | 43301 | 0.25 | Why? |
| Cardiomyopathies | 3 | 2018 | 997 | 0.25 | Why? |
| Observational Studies as Topic | 3 | 2020 | 1887 | 0.25 | Why? |
| Pilot Projects | 10 | 2018 | 5182 | 0.24 | Why? |
| Middle Aged | 72 | 2021 | 270681 | 0.24 | Why? |
| Risk Factors | 36 | 2020 | 71621 | 0.24 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.24 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.24 | Why? |
| Drug Utilization | 4 | 2019 | 619 | 0.24 | Why? |
| Risk Assessment | 17 | 2020 | 25439 | 0.24 | Why? |
| Italy | 15 | 2021 | 38444 | 0.23 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.22 | Why? |
| Acute Disease | 10 | 2018 | 6029 | 0.22 | Why? |
| Neprilysin | 2 | 2019 | 112 | 0.22 | Why? |
| Cardiac Resynchronization Therapy Devices | 2 | 2019 | 64 | 0.22 | Why? |
| Rosuvastatin Calcium | 2 | 2018 | 89 | 0.22 | Why? |
| Metformin | 2 | 2018 | 640 | 0.21 | Why? |
| Equipment Failure | 2 | 2019 | 197 | 0.21 | Why? |
| Diabetes Complications | 3 | 2017 | 2358 | 0.21 | Why? |
| Prognosis | 25 | 2019 | 32490 | 0.20 | Why? |
| Troponin T | 3 | 2017 | 771 | 0.20 | Why? |
| Anemia | 2 | 2017 | 789 | 0.20 | Why? |
| Thrombolytic Therapy | 3 | 2018 | 2218 | 0.20 | Why? |
| Propensity Score | 5 | 2018 | 2690 | 0.20 | Why? |
| Morbidity | 4 | 2019 | 1426 | 0.19 | Why? |
| Pyrimidines | 2 | 2017 | 1557 | 0.19 | Why? |
| Electric Countershock | 2 | 2019 | 284 | 0.19 | Why? |
| Patient Discharge | 4 | 2021 | 5696 | 0.19 | Why? |
| Biphenyl Compounds | 4 | 2019 | 249 | 0.19 | Why? |
| Pericardiocentesis | 1 | 2019 | 84 | 0.19 | Why? |
| ST Elevation Myocardial Infarction | 3 | 2020 | 3051 | 0.19 | Why? |
| Peptic Ulcer | 1 | 2019 | 85 | 0.19 | Why? |
| Hospital Costs | 2 | 2018 | 274 | 0.19 | Why? |
| Medication Adherence | 2 | 2018 | 1270 | 0.18 | Why? |
| Antidotes | 1 | 2018 | 46 | 0.18 | Why? |
| Darbepoetin alfa | 1 | 2017 | 10 | 0.18 | Why? |
| Canrenone | 1 | 2017 | 5 | 0.18 | Why? |
| Diabetic Neuropathies | 1 | 2018 | 64 | 0.18 | Why? |
| Prosthesis-Related Infections | 2 | 2019 | 302 | 0.18 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2018 | 5277 | 0.18 | Why? |
| Furosemide | 1 | 2019 | 99 | 0.18 | Why? |
| Peptides | 4 | 2018 | 2513 | 0.18 | Why? |
| Embolism | 1 | 2019 | 136 | 0.18 | Why? |
| Fumarates | 1 | 2017 | 38 | 0.18 | Why? |
| Digoxin | 1 | 2018 | 68 | 0.18 | Why? |
| Drug Costs | 2 | 2018 | 313 | 0.18 | Why? |
| Judgment | 1 | 2018 | 98 | 0.18 | Why? |
| Prasugrel Hydrochloride | 1 | 2018 | 114 | 0.17 | Why? |
| Thiazolidinediones | 1 | 2017 | 70 | 0.17 | Why? |
| Databases, Factual | 5 | 2018 | 6248 | 0.17 | Why? |
| Fibrinolytic Agents | 2 | 2019 | 1702 | 0.17 | Why? |
| Aged, 80 and over | 25 | 2021 | 88759 | 0.17 | Why? |
| Pulmonary Ventilation | 1 | 2019 | 152 | 0.17 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.17 | Why? |
| Atrial Natriuretic Factor | 1 | 2017 | 75 | 0.17 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 8811 | 0.16 | Why? |
| Galectin 3 | 1 | 2017 | 76 | 0.16 | Why? |
| Renin | 1 | 2017 | 167 | 0.16 | Why? |
| Peripartum Period | 1 | 2017 | 89 | 0.16 | Why? |
| Creatinine | 2 | 2017 | 1443 | 0.16 | Why? |
| Blood Loss, Surgical | 1 | 2018 | 211 | 0.16 | Why? |
| Vascular Calcification | 1 | 2021 | 396 | 0.16 | Why? |
| Postoperative Hemorrhage | 1 | 2018 | 183 | 0.16 | Why? |
| Dose-Response Relationship, Drug | 7 | 2019 | 3776 | 0.16 | Why? |
| Hyperkalemia | 1 | 2017 | 140 | 0.16 | Why? |
| Dabigatran | 1 | 2018 | 204 | 0.16 | Why? |
| Cardiac Tamponade | 1 | 2019 | 165 | 0.15 | Why? |
| Spironolactone | 1 | 2017 | 114 | 0.15 | Why? |
| Thromboembolism | 3 | 2018 | 2101 | 0.15 | Why? |
| Poland | 6 | 2019 | 2368 | 0.15 | Why? |
| Endpoint Determination | 1 | 2017 | 344 | 0.15 | Why? |
| Death, Sudden | 1 | 2017 | 160 | 0.15 | Why? |
| Hypokalemia | 1 | 2017 | 195 | 0.15 | Why? |
| Outpatients | 2 | 2019 | 3417 | 0.14 | Why? |
| Heart Valve Diseases | 1 | 2019 | 355 | 0.14 | Why? |
| Puerperal Disorders | 1 | 2017 | 151 | 0.14 | Why? |
| Potassium | 1 | 2017 | 325 | 0.14 | Why? |
| Practice Guidelines as Topic | 10 | 2019 | 15421 | 0.14 | Why? |
| Patient Care Planning | 1 | 2020 | 582 | 0.14 | Why? |
| Uric Acid | 1 | 2018 | 285 | 0.14 | Why? |
| Prediabetic State | 1 | 2017 | 200 | 0.14 | Why? |
| Wine | 1 | 2015 | 57 | 0.14 | Why? |
| Antithrombins | 1 | 2018 | 353 | 0.14 | Why? |
| Myocardial Infarction | 5 | 2019 | 3361 | 0.14 | Why? |
| Forecasting | 2 | 2019 | 4492 | 0.14 | Why? |
| Comorbidity | 14 | 2020 | 34796 | 0.14 | Why? |
| Endocarditis, Bacterial | 1 | 2019 | 344 | 0.14 | Why? |
| Cardiologists | 1 | 2019 | 366 | 0.14 | Why? |
| Retrospective Studies | 19 | 2021 | 105322 | 0.14 | Why? |
| Healthy Lifestyle | 1 | 2019 | 447 | 0.13 | Why? |
| Administration, Oral | 5 | 2019 | 2340 | 0.13 | Why? |
| Research Report | 1 | 2018 | 376 | 0.13 | Why? |
| Benzhydryl Compounds | 1 | 2017 | 240 | 0.13 | Why? |
| Diabetic Retinopathy | 1 | 2018 | 347 | 0.13 | Why? |
| Oxygen Consumption | 1 | 2019 | 711 | 0.13 | Why? |
| Endocarditis | 1 | 2019 | 368 | 0.13 | Why? |
| Ventricular Function, Left | 3 | 2018 | 1555 | 0.13 | Why? |
| Cholesterol | 1 | 2018 | 660 | 0.13 | Why? |
| Postoperative Complications | 4 | 2019 | 5861 | 0.13 | Why? |
| Cardiovascular System | 2 | 2019 | 750 | 0.13 | Why? |
| Percutaneous Coronary Intervention | 3 | 2018 | 3646 | 0.12 | Why? |
| Glucosides | 1 | 2017 | 359 | 0.12 | Why? |
| Benzaldehydes | 1 | 2011 | 27 | 0.12 | Why? |
| Quality of Life | 6 | 2019 | 9820 | 0.12 | Why? |
| Multicenter Studies as Topic | 2 | 2018 | 2437 | 0.12 | Why? |
| Prevalence | 9 | 2020 | 25773 | 0.12 | Why? |
| Oximes | 1 | 2011 | 51 | 0.12 | Why? |
| Cardiology Service, Hospital | 1 | 2019 | 602 | 0.12 | Why? |
| Respiratory Tract Diseases | 1 | 2020 | 1061 | 0.11 | Why? |
| Aftercare | 2 | 2018 | 1637 | 0.11 | Why? |
| Overweight | 1 | 2018 | 916 | 0.11 | Why? |
| Risk Reduction Behavior | 1 | 2019 | 946 | 0.11 | Why? |
| Troponin | 1 | 2017 | 1058 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Drug Administration Schedule | 4 | 2019 | 2324 | 0.11 | Why? |
| Dyslipidemias | 1 | 2018 | 791 | 0.11 | Why? |
| Pneumonia, Viral | 7 | 2021 | 243684 | 0.11 | Why? |
| Myocardial Ischemia | 1 | 2018 | 781 | 0.11 | Why? |
| Computed Tomography Angiography | 1 | 2021 | 2153 | 0.11 | Why? |
| Metabolic Syndrome | 1 | 2018 | 810 | 0.11 | Why? |
| Antihypertensive Agents | 2 | 2017 | 1962 | 0.11 | Why? |
| Patient Admission | 2 | 2018 | 5250 | 0.10 | Why? |
| Ventricular Dysfunction, Left | 2 | 2017 | 993 | 0.10 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.10 | Why? |
| Data Collection | 1 | 2020 | 1769 | 0.10 | Why? |
| Cost-Benefit Analysis | 2 | 2018 | 2259 | 0.10 | Why? |
| Incidence | 11 | 2019 | 25622 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Biomedical Research | 2 | 2020 | 5270 | 0.10 | Why? |
| Pregnancy Outcome | 3 | 2019 | 3803 | 0.10 | Why? |
| Hemodynamics | 1 | 2018 | 1562 | 0.10 | Why? |
| Informed Consent | 1 | 2017 | 890 | 0.10 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 1458 | 0.10 | Why? |
| Biomarkers | 12 | 2018 | 23361 | 0.10 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.10 | Why? |
| General Practice | 1 | 2018 | 718 | 0.10 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.10 | Why? |
| Insulin | 1 | 2018 | 1316 | 0.09 | Why? |
| Hemorrhage | 5 | 2019 | 3013 | 0.09 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.09 | Why? |
| Health Status | 3 | 2019 | 3259 | 0.09 | Why? |
| Exercise Therapy | 1 | 2017 | 976 | 0.09 | Why? |
| Quality of Health Care | 1 | 2020 | 1948 | 0.09 | Why? |
| Patient Safety | 2 | 2020 | 4885 | 0.09 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.09 | Why? |
| Periodicals as Topic | 1 | 2020 | 1492 | 0.09 | Why? |
| Referral and Consultation | 2 | 2020 | 4816 | 0.08 | Why? |
| Research | 1 | 2020 | 2115 | 0.08 | Why? |
| Norepinephrine | 1 | 2007 | 152 | 0.08 | Why? |
| Delivery of Health Care, Integrated | 1 | 2019 | 1549 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Adult | 17 | 2020 | 244371 | 0.08 | Why? |
| Defibrillators | 2 | 2018 | 144 | 0.08 | Why? |
| Smartphone | 1 | 2018 | 1840 | 0.08 | Why? |
| Cardiac Output, Low | 1 | 2006 | 31 | 0.08 | Why? |
| Propanolamines | 1 | 2006 | 47 | 0.08 | Why? |
| Amides | 1 | 2017 | 1864 | 0.08 | Why? |
| Life Style | 1 | 2019 | 2708 | 0.08 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2017 | 3832 | 0.08 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.07 | Why? |
| Health Care Surveys | 3 | 2020 | 2942 | 0.07 | Why? |
| Diabetes Mellitus | 2 | 2018 | 8207 | 0.07 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.07 | Why? |
| Carbazoles | 1 | 2006 | 120 | 0.07 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.07 | Why? |
| Hypotension | 2 | 2019 | 392 | 0.07 | Why? |
| Disease Progression | 3 | 2019 | 13580 | 0.07 | Why? |
| Electronic Health Records | 1 | 2018 | 3492 | 0.07 | Why? |
| Drug Combinations | 3 | 2019 | 3852 | 0.07 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.07 | Why? |
| Survival Analysis | 4 | 2018 | 7592 | 0.07 | Why? |
| Kaplan-Meier Estimate | 3 | 2017 | 4260 | 0.06 | Why? |
| Losartan | 1 | 2004 | 86 | 0.06 | Why? |
| Drug Interactions | 2 | 2021 | 1653 | 0.06 | Why? |
| Alcohol Drinking | 1 | 2015 | 1663 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Patient Compliance | 2 | 2019 | 1468 | 0.06 | Why? |
| ROC Curve | 3 | 2019 | 6024 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.06 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.06 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.06 | Why? |
| Ambulatory Care | 1 | 2018 | 4947 | 0.06 | Why? |
| Potentially Inappropriate Medication List | 1 | 2021 | 55 | 0.05 | Why? |
| Age Factors | 6 | 2019 | 21039 | 0.05 | Why? |
| Sex Factors | 4 | 2019 | 11014 | 0.05 | Why? |
| Protective Factors | 2 | 2019 | 1720 | 0.05 | Why? |
| Benzimidazoles | 1 | 2004 | 275 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.05 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.05 | Why? |
| Heart Diseases | 1 | 2017 | 3503 | 0.05 | Why? |
| Medical Device Recalls | 1 | 2019 | 5 | 0.05 | Why? |
| Enterococcus | 1 | 2019 | 73 | 0.05 | Why? |
| Antidiuretic Hormone Receptor Antagonists | 1 | 2018 | 18 | 0.05 | Why? |
| Sex Distribution | 2 | 2017 | 2083 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.05 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2019 | 93 | 0.05 | Why? |
| Cardiomyopathy, Restrictive | 1 | 2018 | 30 | 0.05 | Why? |
| Aorta, Thoracic | 1 | 2021 | 271 | 0.05 | Why? |
| Vascular System Injuries | 1 | 2019 | 91 | 0.04 | Why? |
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2018 | 56 | 0.04 | Why? |
| Far East | 1 | 2018 | 125 | 0.04 | Why? |
| Hematinics | 1 | 2017 | 48 | 0.04 | Why? |
| Africa, Northern | 1 | 2019 | 539 | 0.04 | Why? |
| South America | 1 | 2019 | 565 | 0.04 | Why? |
| Drugs, Investigational | 1 | 2020 | 198 | 0.04 | Why? |
| Angioedema | 1 | 2019 | 111 | 0.04 | Why? |
| Polypharmacy | 1 | 2020 | 347 | 0.04 | Why? |
| Program Evaluation | 1 | 2006 | 1929 | 0.04 | Why? |
| Hospital Mortality | 5 | 2019 | 22087 | 0.04 | Why? |
| Least-Squares Analysis | 1 | 2017 | 254 | 0.04 | Why? |
| Ventricular Function | 1 | 2017 | 93 | 0.04 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.04 | Why? |
| Sodium-Glucose Transporter 2 | 1 | 2017 | 111 | 0.04 | Why? |
| Galectins | 1 | 2017 | 109 | 0.04 | Why? |
| Mortality | 3 | 2018 | 7132 | 0.04 | Why? |
| Injections, Intravenous | 1 | 2017 | 381 | 0.04 | Why? |
| Hospitals, Low-Volume | 1 | 2017 | 355 | 0.04 | Why? |
| Maternal Age | 1 | 2017 | 244 | 0.04 | Why? |
| Atrial Function, Left | 1 | 2017 | 82 | 0.04 | Why? |
| Age Distribution | 2 | 2017 | 3567 | 0.04 | Why? |
| Sympathetic Nervous System | 1 | 2017 | 111 | 0.04 | Why? |
| Myocardial Revascularization | 1 | 2018 | 267 | 0.04 | Why? |
| Aortic Diseases | 1 | 2021 | 362 | 0.04 | Why? |
| Systole | 1 | 2017 | 252 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.04 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.04 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 193 | 0.04 | Why? |
| Patient Education as Topic | 1 | 2006 | 1476 | 0.04 | Why? |
| Surveys and Questionnaires | 3 | 2018 | 43792 | 0.04 | Why? |
| Residence Characteristics | 2 | 2017 | 1927 | 0.04 | Why? |
| Blood Pressure | 2 | 2017 | 2198 | 0.04 | Why? |
| Maternal Mortality | 1 | 2019 | 461 | 0.04 | Why? |
| Single-Blind Method | 1 | 2019 | 1283 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.04 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.04 | Why? |
| Cardiomyopathy, Dilated | 1 | 2018 | 251 | 0.04 | Why? |
| Death | 1 | 2018 | 334 | 0.04 | Why? |
| Pregnancy | 4 | 2019 | 23879 | 0.04 | Why? |
| Clinical Decision-Making | 2 | 2019 | 3755 | 0.04 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Proportional Hazards Models | 2 | 2017 | 6543 | 0.03 | Why? |
| Aortic Valve | 1 | 2021 | 664 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2019 | 763 | 0.03 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Hospitals, High-Volume | 1 | 2017 | 688 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.03 | Why? |
| Heart Valve Prosthesis | 1 | 2019 | 533 | 0.03 | Why? |
| Age of Onset | 1 | 2015 | 557 | 0.03 | Why? |
| United States | 5 | 2018 | 46150 | 0.03 | Why? |
| Coronary Vessels | 1 | 2021 | 914 | 0.03 | Why? |
| Self Efficacy | 1 | 2019 | 717 | 0.03 | Why? |
| Causality | 1 | 2017 | 857 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Time-to-Treatment | 2 | 2020 | 5883 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Asia | 1 | 2019 | 2399 | 0.03 | Why? |
| Exercise Test | 1 | 2019 | 911 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Exercise Tolerance | 1 | 2017 | 634 | 0.03 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2019 | 1153 | 0.03 | Why? |
| Washington | 1 | 2017 | 1722 | 0.03 | Why? |
| Magnetic Resonance Imaging | 2 | 2019 | 6551 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2019 | 882 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2019 | 1755 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.03 | Why? |
| Echocardiography | 2 | 2019 | 3661 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.03 | Why? |
| Stents | 1 | 2018 | 916 | 0.03 | Why? |
| Publishing | 1 | 2020 | 990 | 0.03 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.03 | Why? |
| Demography | 1 | 2017 | 1660 | 0.02 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.02 | Why? |
| Socioeconomic Factors | 2 | 2017 | 8495 | 0.02 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Health Expenditures | 1 | 2017 | 904 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.02 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.02 | Why? |
| Heart Ventricles | 1 | 2017 | 1139 | 0.02 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.02 | Why? |
| Vasculitis | 1 | 2015 | 691 | 0.02 | Why? |
| Digitalis Glycosides | 1 | 2007 | 2 | 0.02 | Why? |
| Preoperative Care | 1 | 2017 | 1515 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2019 | 2328 | 0.02 | Why? |
| Diet | 1 | 2019 | 2052 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Infant, Newborn | 2 | 2019 | 23105 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Smoking | 1 | 2019 | 3358 | 0.02 | Why? |
| Confidence Intervals | 1 | 2007 | 744 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.02 | Why? |
| Arrhythmias, Cardiac | 1 | 2017 | 2510 | 0.02 | Why? |
| Venous Thrombosis | 1 | 2019 | 2739 | 0.02 | Why? |
| Calcium Channel Blockers | 1 | 2007 | 367 | 0.02 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.02 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.02 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Internet | 1 | 2018 | 6204 | 0.01 | Why? |
| Program Development | 1 | 2006 | 1089 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Thrombosis | 1 | 2019 | 7504 | 0.01 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Depression | 1 | 2015 | 14116 | 0.01 | Why? |
| Inflammation | 1 | 2007 | 13255 | 0.00 | Why? |